


Second Quarter 2024 Earnings

revvity

July 29, 2024



Safe Harbor

This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, plans concerning business development opportunities, acquisitions or divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. A detailed description of these risk factors can be found under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in the embedded [hyperlink](#) and is available on the "Financial Information" section of our website at www.revivity.com.

Key Takeaways

Innovation

Launched AP2400 workflow for T-SPOT.TB latent TB diagnostic test to drive increased automation

Transformation


First anniversary of Revvity in May
Commercial & Operational synergy realization

Performance

Upside driven by Software and Diagnostics offsetting continued Pharma pressure
Strong expense management & Cash flow generation


A Scientific Solutions Company Helping To Solve The World's Greatest Health Challenges From Discovery To Development, and Diagnosis to Cure

2Q24 Revenue Highlights





Segments

● Diagnostics ● Life Sciences




Geographic

● AMERICAS ● APAC ● EU



Product Mix

● RECURRING ● NON-RECURRING




2Q24 Financial Results

ADJUSTED REVENUE	ADJUSTED OP MARGIN	ADJUSTED EPS	FREE CASH FLOW
\$692M	28.7%	\$1.22	\$160M
↓ -2% y/y	↓ -5bps y/y	↑ +1% y/y	\$293M YTD
Organic: -1% M&A: 0% FX: -1%	Adj. Gross Margin: 61.4% -100bps y/y	Adj. Tax Rate: 21.1%	YTD FCF % Adj. NI 108%
		Adj. Net Interest & Other: \$8M	Excludes AES inflows of an additional \$148M in 2Q24

Life Sciences

Product

● REAGENTS ● INSTRUMENTS ● SOFTWARE




REVENUE	AJUSTED OP MARGINS
-6% Organic Growth	35.8%
Reported: -7% M&A: 0% FX: -1%	-220bps y/y

- -MSD decline from both Pharma/Biotech and Academic/Gov't customers
- -Low-teens instruments decline; -HSD decline in reagents due to licensing comp pressure y/y and muted pharma spending
- +High-teens software growth driven by continued SaaS momentum in both new bookings and renewal rates
- Margins pressured yr/yr due to lower volumes

Diagnostics

End Market

● IMMUNODX ● REPRODUCTIVE HEALTH ● APPLIED GENOMICS





REVENUE	AJUSTED OP MARGINS
3% Organic Growth	25.9%
Reported: 1% M&A: 0% FX: -1%	+300 bps y/y

- +HSD ImmunoDX globally, China ImmunoDX flat
- +LSD Reproductive Health with +LSD newborn (+HSD ex. China)
- -LDD Applied Genomics decline driven by muted pharma spending
- Margin expansion driven by commercial and operational synergy realization

2024 Financial Guidance

REVENUE	\$2.77B - \$2.79B
	~1% reported
	Organic: ~2%
	FX: -1%, M&A: 0%
ADJUSTED OP. MARGIN	28.0-28.5%
ADJUSTED EPS	\$4.70 - \$4.80
	Adj. Net interest expense, other: ~\$50M
	Adjusted tax rate: ~20%
	Average diluted share count: 123.5M





Revvity.com